Documents / Official release

AAWSAP DIRD, Biomaterials, January 2010

U.S. Department of War · 2010-01-07 · 32 pages · text from the file's own layer

This Defense Intelligence Reference Document, dated 7 January 2010, was prepared by the Defense Intelligence Agency's Defense Warning Office. It is one of a series of advanced technology reports produced in FY 2009 under the Advanced Aerospace Weapon System Applications program. The report reviews biomaterials used in medicine, including silicones, Teflon, biodegradable polymers, hydrogels, titanium, ceramics and tissue constructs, and applications such as stents, joints, contact lenses, drug delivery and dialysis. It concludes that most innovation lies in new ways to apply existing materials.

From the source: Release of 2026-09-18 Incident: 1/7/10, Las Vegas, Nevada. Released with redactions. This document is a Defense Intelligence Reference Document (DIRD), a technical reference format used by the Defense Intelligence Agency (DIA) to capture baseline knowledge on a specific topic for later analytic use. DIRDs are best understood as reference and synthesis products rather than as original research. It is one of 38 DIRDs produced under the Advanced Aerospace Weapon System Applications Program (AAWSAP) between 2009 and 2011. Because AAWSAP’s scope permitted a broad range of supporting topics, not every DIRD in the series directly concerns aerospace systems or future threat assessment. The following summary reflects the DIRD’s scope and framing at the time of writing and should not be read as implying current validation of the concepts discussed. This DIRD is a broad survey of biomaterials, including metals, polymers, ceramics, glasses, and composites designed to interact with living tissue, and argues that their value depends mainly on biocompatibility, reliability, and careful matching of material properties to specific medical uses. The report reviews major application areas including biosensors, implants, cardiovascular devices, contact lenses, drug delivery systems, tissue constructs, titanium devices, and dialysis membranes, emphasizing that no single biomaterial works best in every setting. Its overall conclusion is that biomaterials are already foundational to a large medical-device industry and save or improve millions of lives, but that progress tends to be slow because safety testing is stringent; as a result, most advances come from improved ways of applying established materials such as silicone, Teflon, biodegradable polymers, ceramics, and titanium in new devices and clinical settings rather than from radically new substances.

UNCLASSIFIED// POI\ OPPICl"L U.!E! Oflt (
Numbers of Medical Devices/yr. Worldwi,.,......--
intraocular lens 7,000,
contact lens 75,000,000
vascular graft 400,000
hip and knee prostheses 1,000,000
catheter 300,000,000
heart valve 200,000
stent (cardiovascular) >2,000,000
breast implant 300,000
dental implant 500,000
pacemaker 200,000
renal d ialyzer 25,000,000
left ventricular assist devices 100,000
Millions of lives saved. The quality of Life improved for millions more.
A $100 billion industry
Figure 2. Common Medical Devices That Use Biomaterials
The development of biomaterials is the junction of materials science and
chemistry. Medical devices may be composed of a single biomaterial or a
combination of several materials. A heart valve might be fabricated from
polymers, metals, and carbons. A hip joint might be fabricated from metals
and polymers (and sometimes ceramics) and will be interfaced to the body
through a polymeric bone cement.
Biomaterials by themselves do not make a useful clinical therapy but rather
have to be fabricated into devices. This is typically an engineer's role, but the
engineer might work closely with synthetic chemists to optimize material
properties and with physicians to ensure the device is useful in clinical
applications.
Biomaterials must be compatible with the body, and there are often issues
that must be resolved before a product can be placed on the market and used
in a clinical setting. Because of this, biomaterials are usually subjected to the
same very stringent safety requirements as those of new drug therapies.
UNCLASSIFIED/ ,,roA &FFI@IAL U:!E: Oflt I
viii

Not linked to a story yet.

About this file

Official release, from the pursue collection. The PDF is mirrored here; the original link is above. 32 pages are in the text index: search them above, or from the library's search.